Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 4/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447452 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL288838 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL5650822 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL3837973 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL743357 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL15775826 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL7356486 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL4275825 | 0.92 | KLK5 (0.58) | KLK5ATMACECTSSCTSK | |
| SCHEMBL4955577 | 0.92 | KLK5 (0.58) | KLK5ATMACECTSSCTSK | |
| SCHEMBL6343884 | 0.90 | KLK5 (0.60) | KLK5ATMACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702005-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | Metabolon Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | METABOLON INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | WESTVAC BIOPHARMA CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4488264-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | WestVac Biopharma Co., Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024227056-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | METABOLON INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-116693447-B | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024110757-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | KING'S COLLEGE LONDON (GB) | 2024-05-30 | — | — | WO | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
| US-5688946-A | DIPEPTIDES FOR HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | HOFFMANN LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5656603-A | INHIBITING BRANDYKININ DEGRADATION | LOYOLA UNIVERSITY OF CHICAGO (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996039163-A1 | AMINOPEPTIDASE P INHIBITORS AND USES THEREOF | LOYOLA UNIVERSITY OF CHICAGO (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-4668769-A | Oxa- and azahomocyclostatine polypeptides | PFIZER INC. | 1987-05-26 | — | — | US | disclosed |
| EP-0211580-A2 | Renin inhibiting polypeptides and intermediates therefor | PFIZER INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4599198-A | Intermediates in polypeptide synthesis | PFIZER INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4473554-A | Bestatin-related compounds as immunopotentiator | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-09-25 | — | — | US | disclosed |
| US-4395402-A | ENKEPHALIN IN HIBITOR, SYNERGISTIC COMPOUND WITH MORPHINE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KANKYU KAI (JP) | 1983-07-26 | — | — | US | disclosed |
| US-4370318-A | Bestatin-related compounds as immunopotentiator | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | KLK5 2838/4885ATM 3383/4885ACE 3963/4885 |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ACE2, ACE, PKD2 | KLK5 371/4885ATM 4579/4885ACE 2/4885 |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | CNDP2, DPP7, DPEP1 | KLK5 1947/4885ATM 3585/4885ACE 108/4885 |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | KLK5 2838/4885ATM 3383/4885ACE 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.